South Africa: What Are Broadly Neutralising Antibodies and What Do They Mean for the Fight Against HIV?

What the report says

AllAfrica published a briefing from Cape Town by Catherine Tomlinson on 24 August 2026 explaining broadly neutralising antibodies, or bNAbs, and why HIV researchers think they could matter for prevention and treatment. The piece says HIV can evade ordinary immune defences by changing the surface targets that antibodies recognise, while a smaller share of people living with HIV eventually develop antibodies that can attack more conserved parts of the virus.

The article says bNAbs have been studied since the 1990s and can now be made in the laboratory, with early trials suggesting they can be given safely and can be engineered to last longer or work more strongly. Researchers are testing them as injections or infusions for people who are HIV negative, as well as for people living with HIV, and are also trying to design vaccines that would prompt the body to make bNAbs naturally. However, the report stresses that this work remains early-stage and that antiretroviral medicines are still the only proven HIV treatment and a highly effective prevention tool.

On prevention, the story notes that earlier AMP trials of a single bNAb, VRC01, did not stop infection overall, although they showed that some viral strains were vulnerable. That has pushed scientists toward combinations of bNAbs that cover more viral variants, including planned studies such as Combo-AMP. The article also cites CAPRISA’s CAPRISA 012C trial in young women in Southern Africa, which did not prevent infection but offered useful data for future research, especially around viral sensitivity.

On treatment, the article says researchers are asking whether bNAbs could help control the virus for longer without ongoing antiretroviral therapy, but that the approach has not yet reached that goal.